Clinical Trial

Photobiomodulation Therapy for the Management of Breast Cancer-related Lymphedema

Study acronym: LymphLight
Recruiting
View on ClinicalTrials.gov →
Summary
Up to one out of five patients with breast cancer will develop lymphedema in the upper extremity after cancer treatment. Patients with breast cancer-related lymphedema (BCRL) suffer from pain, heaviness, tightness, and a decreased range of motion. Photobiomodulation therapy (PBMT) is a non-invasive therapy based on the application of visible and/or near-infrared light produced by a laser diode or a light-emitting diode. The scientifically proven biologic effects of PBM are improved wound healing, and a reduction in pain, inflammation, and oedema. Therefore, the aim of this study is to evaluate the effectiveness of PBMT on the management of BCRL.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-12-28; most recent amendment 2023-02-27.
Status change: Not Yet Recruiting → Recruiting 2021-03-24
Trial Details
NCT Number NCT04690439
Lead Sponsor Jessa Hospital
Collaborators: Hasselt University
Conditions Breast Cancer, Breast Cancer Related Lymphedema, Lymphedema of Upper Arm
Enrollment 104 participants
Start Date 2021-02-22
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2023-02-28